FDA
-
-
-
-
-
-
-
FDA selects 7 companies for domestic drug manufacturing pilot
-
-
-
-
-
-
-
Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
-
-
-
-
-
-
-
Lilly reports weight loss data for Foundayo across menopause stages
-
-
-
-
-
-
-
Lilly's Retevmo reduces cancer recurrence risk by 83% in trial
-
-
-
-
-
-
-
Lilly's VERVE-102 reduces cholesterol by up to 62% in phase 1b trial
-
-
-
-
-
-
-
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
-
-
-
-
-
-
-
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
-
325,447 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

